Efficacy and safety benefits of <scp>HR17031</scp> , a fixed‐ratio combination of <scp>INS068</scp> and noiiglutide, versus its components alone in Chinese patients with type 2 diabetes uncontrolled on oral antidiabetic drug(s): A phase 2, multicentre, open‐label, randomised, parallel three‐arm, treat‐to‐target trial

Linong Ji, Zi Ye, Li Lü et al.|Diabetes Obesity and Metabolism|2025

Cited by 1